Abstracto

Harnessing the Antitumor Potential of CD8+ T Cells with Fewer Side Effects

Shane Crude

CD8+ T cells, known as cytotoxic T lymphocytes (CTLs), have emerged as a critical component of the immune system with potent antitumor potential. These specialized immune cells can recognize and eliminate cancer cells, offering promising avenues for cancer immunotherapy. CD8+ T cells exhibit the ability to recognize tumor-associated antigens, trigger immune responses, and exert cytotoxic effects on cancer cells through the release of cytotoxic molecules. However, maximizing the efficacy of CD8+ T cells while minimizing associated side effects remains a challenge.